ISO 10993-1:2025: What FDA's Partial Recognition Means for Your Biocompatibility File

On 25 May 2026, the way medical device companies prove the biological safety of their products quietly changed. The United States Food and Drug Administration added the newest edition of the world's central biocompatibility standard, ISO 10993-1:2025, to its list of recognized consensus standards. It did so through partial recognition, which means most of the standard is accepted as valid evidence while specific parts are not. For any company that sells devices in the United States, or plans to, this reset the expectations for every biocompatibility file now in preparation.

The change matters because biocompatibility is one of the most common reasons a device submission stalls. A test plan built around the wrong edition of the standard, or built on the parts the FDA has chosen not to recognize, can trigger a deficiency letter that adds months to a review. The reassuring part is that the agency has given industry a defined runway. This guide explains what the FDA recognized, what it did not, how the 2025 edition differs from the 2018 version, and the practical steps Canadian and international device makers should take before the transition window closes on 1 July 2029.

Executive summary

ISO 10993-1 is the master standard for the biological evaluation of medical devices. It sets the framework for deciding which biocompatibility tests a device needs, based on how and for how long the device contacts the body, all inside a risk management process. On 25 May 2026 the FDA added the sixth edition, ISO 10993-1:2025, to its recognized consensus standards database under Recognition List Number 066, with partial recognition. Declarations of conformity to the previous edition, ISO 10993-1:2018, will be accepted until 1 July 2029, after which only the 2025 edition will support a declaration of conformity. Two parts of the new edition are expressly not recognized, and the agency has flagged several technical areas, including genotoxicity, where its own position differs from the standard. Device makers should re-map their biocompatibility strategy to the recognized portions of the 2025 edition now, rather than discovering a gap at submission.

What FDA announced, in plain terms

What it is. The FDA added ISO 10993-1:2025, the sixth edition of the biocompatibility master standard, to its list of recognized consensus standards for medical devices with an effective recognition date of 25 May 2026. A recognized standard is one the FDA will accept as valid supporting evidence when a manufacturer submits a declaration of conformity, which is a signed statement that a device meets the standard.

Why it matters. When a standard is recognized, conforming to it can replace pages of primary data in a submission and speed the review. When only part of a standard is recognized, the unrecognized parts carry no such weight, and the agency will apply its own expectations there instead. Building a file on an unrecognized clause is a silent risk that surfaces only when a reviewer raises a deficiency.

What to do. Confirm which edition your current biological evaluation plan cites, identify whether any of your reasoning relies on the parts FDA did not recognize, and plan your move to the 2025 edition before the 1 July 2029 deadline. The essential facts are summarised below.

Item	Detail
Standard	ISO 10993-1:2025, sixth edition (Biological evaluation of medical devices, Part 1)
FDA action	Partial recognition as a consensus standard
Recognition date	25 May 2026 (Recognition List Number 066)
Prior edition	ISO 10993-1:2018 (Recognition Number 2-258)
Transition deadline	Declarations of conformity to the 2018 edition accepted until 1 July 2029
Not recognized	Reference to consumer products in clause 6.5.11.3, and clause 6.9 on biological risk estimation

What ISO 10993-1 actually is

ISO 10993-1 does not tell you to run every test in the toolbox. It tells you how to decide which tests are needed. The standard classifies a device by the nature of its body contact, being surface contact, contact with breached or compromised surfaces, external communication, or implant, and by the duration of contact, being limited (up to 24 hours), prolonged (over 24 hours to 30 days), or long term (over 30 days). Those two axes point to a set of biological endpoints to consider, such as cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation effects, and haemocompatibility.

The full title of the 2025 edition reflects a deliberate shift in emphasis: Biological evaluation of medical devices, Part 1, Requirements and general principles for the evaluation of biological safety within a risk management process. The move is away from a fixed checklist of animal tests and toward a documented, risk based evaluation that leans on chemical characterization and existing data before new testing. This is the same risk management logic used in ISO 14971, which sits at the centre of every modern device quality system. Getting the classification right at the start is the single highest leverage step, because it defines the entire evaluation that follows.

What FDA did not recognize: the extent of recognition

What it is. Partial recognition means the FDA published an extent of recognition that names the parts of the standard it will not accept as conformity evidence. For ISO 10993-1:2025, two elements are excluded, and the agency has flagged further technical differences that manufacturers must reconcile against the FDA's own biocompatibility guidance.

Why it matters. Where the FDA does not recognize a clause, the agency's guidance controls. A device maker who relies on the standard alone in those areas will be asked for more, so the safest path is to align with the FDA position from the first draft of the evaluation plan.

Area	FDA position	Practical effect
Clause 6.5.11.3 (consumer products reference)	Not recognized; conflicts with FDA biocompatibility guidance	Do not rely on the consumer products carve out to reduce testing for low risk skin contact
Clause 6.9 (biological risk estimation)	Not recognized; conflicts with ISO 14971 risk sections	Use ISO 14971 risk estimation, evaluation and control, not the clause 6.9 approach
Genotoxicity	FDA expects genotoxicity for a broader set of contact categories than the standard indicates	Follow the FDA framework, which can require genotoxicity where the standard would not
Material mediated pyrogenicity	FDA continues to treat it as an endpoint to address	Keep pyrogenicity in the evaluation even though the 2025 edition de-emphasises it

How the 2025 edition differs from 2018

The direction of the 2025 edition continues a decade long trend: reduce unnecessary animal testing and strengthen the evidence chain that justifies each decision. In practice, the newer edition places more weight on chemical characterization and toxicological risk assessment as a route to address endpoints, expects a clearer, documented rationale for every test that is or is not performed, and tightens the language around when existing data can stand in for new studies. It also refines the guidance on nanomaterials and on how to handle particulates and degradation products.

For manufacturers, the shift rewards good data management. A company that already holds well organised material composition data, extractables and leachables results, and a defensible risk file will find the 2025 edition easier to satisfy. A company that has relied on a fixed panel of biological tests without a strong rationale will feel more pressure to build one. This is where a structured quality system and a current risk file pay for themselves.

The transition timeline you cannot ignore

What to do. The FDA will accept declarations of conformity to ISO 10993-1:2018 until 1 July 2029. After that date, a declaration of conformity must cite the 2025 edition. That sounds distant, but device development, testing, and submission cycles are long. A device entering design today may not submit for two to three years, which places it squarely inside the changeover. Treat 1 July 2029 as the date by which your evaluation approach, not just your paperwork, should already be built on the recognized parts of the 2025 edition.

Timeframe	What applies
Now to 1 July 2029	Declarations of conformity may cite ISO 10993-1:2018 or the recognized parts of ISO 10993-1:2025
From 2 July 2029	Declarations of conformity must cite ISO 10993-1:2025 (recognized parts); the 2018 declaration is no longer accepted
All periods	Where FDA does not recognize a clause, FDA biocompatibility guidance applies regardless of edition

What this means for Canadian and cross-border device makers

Canadian manufacturers who file with both Health Canada and the FDA gain the most from a single, harmonised biocompatibility file. Health Canada also relies on the ISO 10993 series, and biological safety data are central to a Class III or IV medical device licence application as well as to a United States submission. The practical goal is one evaluation that satisfies both regulators, with the FDA extent of recognition treated as the stricter overlay. Because a declaration of conformity is often the fastest way to close a biocompatibility section, understanding how FDA recognized consensus standards and the declaration of conformity work is worth the effort for any cross-border programme.

The change also lands at the same time as the FDA's transition to the Quality Management System Regulation, which harmonises with ISO 13485. A biocompatibility file does not live in isolation. It draws on design controls, risk management, supplier data, and change control, all of which sit inside the quality system. Firms that are already tightening their systems for the FDA QMSR and ISO 13485 should fold the ISO 10993-1:2025 changes into that same effort rather than run a separate project.

Compliance checklist: preparing for ISO 10993-1:2025

Use the following steps to move a biocompatibility programme onto solid ground before the transition deadline.

Confirm the edition. Check which edition each biological evaluation plan and report currently cites, and list every open or planned submission affected.
Map to the extent of recognition. Identify any reliance on clause 6.5.11.3, clause 6.9, or an assumption about genotoxicity or pyrogenicity that the FDA does not recognize, and correct it.
Refresh the device categorization. Re-confirm contact type and duration for each device, since these drive the required endpoints.
Strengthen chemical characterization. Ensure material composition, extractables and leachables data, and the toxicological risk assessment are current and defensible.
Align the risk file. Use ISO 14971 for risk estimation and control, and document how biological risks feed the overall risk management report.
Engage the FDA early where needed. For novel materials or unclear genotoxicity expectations, use a pre-submission to confirm the testing plan before spending on studies.
Book testing capacity early. Reserve laboratory slots well ahead of the deadline to avoid a queue that delays submission.
Update SOPs and templates. Revise the biological evaluation plan template and declaration of conformity to reflect the 2025 edition and the FDA extent of recognition.

Common mistakes to avoid

Treating recognition as full acceptance and citing the whole standard in a declaration of conformity, including the clauses FDA does not recognize.
Assuming the 2029 deadline is far enough away to defer action, then colliding with long testing lead times.
Skipping chemical characterization and defaulting to a fixed panel of biological tests without a documented rationale.
Underestimating genotoxicity, where the FDA can expect more than the standard indicates for certain contact categories.
Running the biocompatibility update as a standalone task rather than inside the design controls, risk, and quality system that support it.

Frequently asked questions

What is ISO 10993-1:2025 and does FDA require it?

ISO 10993-1:2025 is the sixth edition of the master standard for the biological evaluation of medical devices. The FDA does not mandate any single standard, but it recognizes ISO 10993-1:2025 with partial recognition, so conforming to the recognized parts is the most efficient way to support the biocompatibility section of a submission. Where FDA does not recognize a clause, its own biocompatibility guidance applies instead.

When does the transition from ISO 10993-1:2018 take effect?

The FDA will accept declarations of conformity to ISO 10993-1:2018 until 1 July 2029. From 2 July 2029, a declaration of conformity must cite the 2025 edition. Because development and testing cycles are long, manufacturers should plan the change well before that date.

What parts of ISO 10993-1:2025 did FDA not recognize?

The FDA does not recognize the reference to consumer products in clause 6.5.11.3, nor clause 6.9 on biological risk estimation, because they conflict with FDA biocompatibility guidance and with ISO 14971 risk management. The agency has also signalled that its expectations for genotoxicity and material mediated pyrogenicity can differ from the standard.

Does partial recognition mean the standard is weaker?

No. Partial recognition simply means the FDA accepts most of the standard as conformity evidence while carving out specific clauses. Manufacturers may still follow the whole standard, but a declaration of conformity only shortens review for the recognized parts, and the FDA position governs the rest.

How does this affect a Health Canada medical device licence?

Health Canada also relies on the ISO 10993 series for biological safety. A single, well built biocompatibility file can support both a Canadian medical device licence and a United States submission. Treat the FDA extent of recognition as the stricter overlay so the same evaluation serves both markets.

What is the first step if our file still cites the 2018 edition?

Run a gap assessment. Confirm the edition cited, map any reliance on unrecognized clauses, refresh the device categorization and chemical characterization, and align the risk file to ISO 14971. That assessment tells you whether a documentation update is enough or whether new testing is required.

How MFLRC can help

MFLRC helps medical device companies turn a standards change into a clean, defensible file. We run biocompatibility gap assessments against ISO 10993-1:2025 and the FDA extent of recognition, build or refresh the biological evaluation plan, and align it with the risk file and quality system. Our pharmaceutical and device validation services cover method, process, and packaging validation that a submission depends on, while our audit and inspection-readiness services confirm the file will hold up under scrutiny. For companies entering or expanding in Canada, our medical device regulatory support ties the biocompatibility work to the licence pathway so one effort serves both regulators.

Not sure if your biocompatibility file meets the new ISO 10993-1:2025 risk based framework? A short gap assessment before your next 510(k), PMA, or Health Canada submission is the most cost effective insurance against a biocompatibility deficiency.

Book a Biocompatibility Gap Assessment

Conclusion

The FDA's partial recognition of ISO 10993-1:2025 is not a paperwork footnote. It resets the evidence expectations for every biocompatibility file, rewards good chemical characterization and risk management, and puts a firm date on the transition away from the 2018 edition. Companies that act now, by confirming their edition, mapping the extent of recognition, and aligning testing and documentation, will move through review with fewer surprises. Those that wait risk a deficiency, a testing queue, or both. The standard has changed, and the smart response is to change with it, deliberately and early.